Quarterly ResultAug 3, 2026, 04:08 PM
Keros Therapeutics Q2 Net Loss $28.7M; R&D Down 48.7%
AI Summary
Keros Therapeutics reported a net loss of $28.7 million for Q2 2026, a decrease from $30.7 million in Q2 2025. Research and development expenses significantly decreased by $21.2 million to $22.3 million, primarily due to the transition of elritercept-related expenses to Takeda and a 2025 corporate restructuring. General and administrative expenses also fell to $8.6 million. The company initiated a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy and expects initial data in H1 2027, while maintaining a cash position of $257.6 million, sufficient to fund operations into H1 2028.
Key Highlights
- Net loss for Q2 2026 was $28.7 million, down from $30.7 million in Q2 2025.
- Research and development expenses decreased 48.7% to $22.3 million in Q2 2026.
- General and administrative expenses decreased 40.7% to $8.6 million in Q2 2026.
- Cash and cash equivalents were $257.6 million as of June 30, 2026.
- Cash runway expected into the first half of 2028.
- Initiated Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy.
- Expects initial rinvatercept Phase 2 data in H1 2027.
Price Impact
More from KROS